Exonhit enters into Research Agreement with. Pfizer to identify Alzheimer's disease biomarkers. Monday October 10
bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration. Development of blood diagnostics for the early detection of cancers.
ExonHit. Therapeutics is exploiting its understanding of mRNA splicing to enable it to identify promising diagnostic and therapeutic tar-.
11 sept. 2008 8 biomarkers. Licensing/theranostics: Merck assay... NucliSENS EasyQ®. Mixed units: Shanghai
E-mail: laurent.desire@exonhit.com. Abbreviations used: Ab beta amyloid; ADAM
de la technologie de biopuces d'ExonHit SA [3] et ayant la capacité de différen- cier une tumeur mammaire maligne de lésions bénignes
ExonHit Therapeutics (Paris) has announced the appointments of Florence. Abrahamian as financial director Jim Liddy as vice president
?Correspondence to: Laurent Désiré Exonhit SA
Exonhit. X. X. X. Page 3. Hypertension artérielle. Page 4. Lancet 2010; 375: 895–905. 4 études. UK-TIA=2 435. ESPS1=2 500. Dutch TIA n=3 150.
4 avr. 2011 http://www.decode.com/news/news.php?story=156 October 102011 Exonhit enters into. Research Agreement with Pfizer to!identify Alzheimer's ...